Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0352W HIGH $5.39
Volume
7.57 K
Value Traded
63.61 K
Short % Float
4%
-16.41%Week
-29.14%1 Month
-47.03%3 Month
-63.36%6 Month
-99.03%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.12 M
EPS (TTM)
-2.62
P/E Ratio
-
Ent. Value
-860.18 K
Total Shares
5.61 M
Float Shares
4.84 M
Insiders
13.81%
Institutions
5.68%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
IMNN Catalyst Timeline
Dated clinical, regulatory and corporate events for Imunon, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Imunon, Inc.
729Total events
10Upcoming
139Tier-1 (high impact)
2011 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Debt Royalty FinancingCorporate
IMUNON exchanges $1.2M of A-1 Note debt for Series B Preferred Stock
▲Enrollment UpdateIMNN-001FiledTrial
OVATION 3 enrollment ahead of plan
newly diagnosed advanced ovarian cancersource ↗
▲Biomarker DataIMNN-001FiledClinical Data
Preliminary MRD study clinical and translational findings
minimal residual disease in ovarian cancersource ↗
▲Long Term DataIMNN-001FiledClinical Data
OVATION 1 participant nearly 10 years from diagnosis, free of recurrence
advanced ovarian cancersource ↗
▲DSMB ReviewIMNN-001FiledTrial
IDMC recommends continuation of Phase 2 MRD study of IMNN-001 without modification following safety review
newly diagnosed advanced ovarian cancersource ↗
▲Safety Data UpdateIMNN-001FiledClinical Data
Favorable safety data for IMNN-001 in Phase 2 MRD study: no CRS, systemic toxicities or serious immune-related AEs
newly diagnosed advanced ovarian cancersource ↗
▲Partnership / LicenseIMNN-001FiledCorporate
IMUNON enters CRADA with NCI's Cancer Therapy Evaluation Program for IMNN-001
solid tumorssource ↗
▲Biomarker DataIMNN-001FiledClinical Data
Preliminary MRD study data: MRD-positive rate, ctDNA clearance, no evidence of disease, biomarker findings
minimal residual disease in ovarian cancersource ↗
▲Long Term DataIMNN-001FiledClinical Data
OVATION 1 participant almost 10 years from diagnosis, free of cancer recurrence
newly diagnosed advanced ovarian cancersource ↗
▲DSMB ReviewIMNN-001FiledTrial
Independent data monitoring committee recommended MRD study continuation without modification
minimal residual disease in ovarian cancersource ↗
▲Enrollment UpdateIMNN-001FiledTrial
Enrollment rate exceeding forecast in OVATION 3
advanced ovarian cancersource ↗
▲Safety Data UpdateIMNN-001FiledClinical Data
Favorable safety profile reported in OVATION 3
advanced ovarian cancersource ↗
▲DSMB ReviewIMNN-001FiledTrial
IDMC review of OVATION 3 raised no safety issues
advanced ovarian cancersource ↗
▲Trial InitiationIMNN-001FiledTrial
First patient randomized in OVATION 3
advanced ovarian cancersource ↗
●Trial CompletionIMNN-101Trial
First-in-human study of IMNN-101 completed dosing
COVID-19 boostersource ↗
▲Full ResultsIMNN-001FiledClinical Data
Final results from OVATION-2 showing 14.7 month median OS increase
advanced ovarian cancersource ↗
▲Topline ReadoutIMNN-001FiledClinical Data
Positive preliminary Phase 2 MRD data for IMNN-001
newly diagnosed advanced ovarian cancersource ↗
◆Enrollment UpdateIMNN-001FiledTrial
Phase 3 OVATION 3 trial rapidly recruiting
newly diagnosed advanced ovarian cancersource ↗
▲Full ResultsIMNN-001FiledClinical Data
Completed Phase 2 OVATION 2 results: 14.7-month median OS increase
newly diagnosed advanced ovarian cancersource ↗
◆Poster PresentationIMNN-001FiledPresentation
Poster presentation at AACR D3 conference
advanced ovarian cancersource ↗
▲Additional DataIMNN-001FiledClinical Data
Encouraging preliminary Phase 2 MRD data for IMNN-001 reported in July 2026
newly diagnosed advanced ovarian cancersource ↗
▲Biomarker DataIMNN-001FiledClinical Data
Translational analyses show IMNN-001 remodels tumor immune microenvironment from cold to hot
newly diagnosed advanced ovarian cancer (minimal residual disease)source ↗
▲DSMB ReviewIMNN-001FiledTrial
iDMC recommends continuation of OVATION 3 without modification
newly diagnosed advanced ovarian cancersource ↗
◆Enrollment UpdateIMNN-001FiledTrial
27 patients enrolled to date
newly diagnosed advanced ovarian cancersource ↗
▼Equity OfferingCorporate
Up to $10 million cash financing including preferred stock and promissory notes
▲Full ResultsIMNN-001FiledClinical Data
Updated Phase 2 final data showing 14.7-month median OS improvement
newly diagnosed advanced ovarian cancersource ↗
◆Enrollment UpdateIMNN-001FiledTrial
Phase 3 OVATION 3 study currently enrolling
newly diagnosed advanced ovarian cancersource ↗
▲DSMB ReviewIMNN-001FiledTrial
Independent data monitoring committee recommended OVATION 3 continuation without modification
newly diagnosed advanced ovarian cancersource ↗
◆Quarterly UpdateCorporate
First Quarter 2026 Financial Results and Business Update Conference Call
▲Enrollment UpdateIMNN-001FiledTrial
Enrollment in OVATION 3 continues ahead of plan
newly diagnosed advanced ovarian cancersource ↗
▲FDA Feedback ReceivedIMNN-001FiledFDA Meeting
FDA reviewed and aligned with Phase 3 protocol, confirms path to BLA filing
newly diagnosed advanced ovarian cancersource ↗
▲Full ResultsIMNN-001FiledClinical Data
Final data analysis from OVATION 2 shows median OS improvement of 14.7 months
newly diagnosed advanced ovarian cancersource ↗
▲Enrollment UpdateIMNN-001FiledTrial
Enrollment in Phase 3 OVATION 3 trial remains ahead of plan
newly diagnosed advanced ovarian cancersource ↗
◆Management ChangeCorporate
Chief Scientific Officer Khursheed Anwer to retire effective February 20, 2026
▼Restructuring LayoffsCorporate
Strategic reorganization to reduce operating expenses and focus on Phase 3 OVATION 3 Study
▲Enrollment UpdateIMNN-001FiledTrial
Phase 3 OVATION 3 enrollment remains ahead of schedule
newly diagnosed advanced ovarian cancersource ↗
▲Trial InitiationIMNN-001FiledTrial
Phase 3 OVATION 3 trial currently enrolling patients at five clinical sites
newly diagnosed advanced ovarian cancersource ↗
▲Enrollment UpdateIMNN-001FiledTrial
Enrollment continues to generate strong interest in OVATION 3
newly diagnosed advanced ovarian cancersource ↗
◆Enrollment UpdateIMNN-001FiledTrial
Goal of 20 clinical sites activated by end of 2025
newly diagnosed advanced ovarian cancersource ↗
▲Topline ReadoutIMNN-001FiledClinical Data
Final randomized Phase 2 OVATION 2 overall survival results (14.7-month median OS difference)
newly diagnosed advanced ovarian cancersource ↗
◆Quarterly UpdateCorporate
Third Quarter 2025 Financial Results and Business Update Conference Call
◆Oral PresentationIMNN-001FiledPresentation
Public webcast presenting clinical data and insights for IMNN-001 in ovarian cancer
advanced ovarian cancersource ↗
◆R&D DayPresentation
R&D Day in New York City with presentations on IMNN-001 and OVATION 3 Study
Past FDA Catalysts and PDUFA Decisions
How IMNN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-23 | IMNN-001 | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D31 / 100
Pipeline Score
$3M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.4x
rNPV / MCap
Top 65%
Micro Cap(rank 428 of 658)
Percentile Rank
Imunon, Inc. faces pipeline headwinds (31/100), with $500M risk-adjusted pipeline value, led by IMNN-101 in SARS CoV 2 Infection (Phase 1), across $82B in total addressable markets, but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IMNN-101 Monoclonal antibodyCompletedNCT06283459 | SARS CoV 2 Infection | Phase 1 | COMPLETED | 24 | Mar 7, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every IMNN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| IMNN-001 | advanced ovarian cancer | Phase 2 | 2026-09-24 | 14.7-month median overall survival improvement; 45.1 months median overall survival for IMNN-001 plus chemotherapy; 30.4 months median overall survival for standard of care aloneRead More | IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of PlanRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Eylward SusanOfficer (General Counsel and Corp Sec) | Sell | -2,525 2,896 held | $1.56 | 08/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IMNN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in IMNN for Q2 2026. | ||||
IMNN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IMNN ranks across every disease it competes in
Competitive Position is a premium feature
See how IMNN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIMNN News
IMNN▼ -6.1%on this news
IMUNON to Participate in Upcoming Investor Conferences
IMUNON, Inc. has announced its participation in two upcoming investor conferences in October 2026. CEO Stacy Lindborg will present at the Maxim Growth Summit and the ThinkEquity Conference, highlighting the company's focus on DNA-mediated immunotherapies. The company will also host one-on-one meetings with investors during these events.
Read more →IMNNIMUNON Converts $1.2 Million of Debt-to-Equity
IMUNON, Inc. has successfully converted $1.2 million of debt into non-convertible Series B Preferred Stock, reducing its outstanding debt by 43%. This strategic move enhances shareholder equity while avoiding the issuance of common stock or dilutive warrants. The company aims to bolster its financial position to support ongoing clinical strategies.
Read more →IMNN▼ -8.2%on this newsshared move
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
IMUNON, Inc. presented updates on its IMNN-001 program for advanced ovarian cancer, highlighting a significant 14.7-month median overall survival improvement in a Phase 2 study. The ongoing Phase 3 OVATION 3 trial aims to confirm these results, with promising safety data indicating a favorable profile compared to historical IL-12 therapies. Enrollment is ahead of schedule, targeting completion by early 2029.
Read more →IMNN▲ +5.6%on this newsshared move
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
IMUNON's Phase 2 MRD study of IMNN-001 has received a recommendation from the Independent Data Monitoring Committee to continue without modification after a favorable safety review. No serious adverse events were observed, supporting the safety profile of the IL-12-based immunotherapy. Preliminary data indicates promising anti-tumor activity, enhancing confidence in the ongoing Phase 3 OVATION 3 trial.
Read more →IMNN▼ -11.6%on this news
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
IMUNON has entered a Cooperative Research and Development Agreement with the National Cancer Institute to advance the clinical development of IMNN-001, a DNA-based immunotherapy. This collaboration will evaluate IMNN-001 in new solid tumor indications and combination regimens, leveraging NCI's resources. The partnership aims to enhance the ongoing Phase 3 OVATION 3 study in ovarian cancer.
Read more →IMNNIMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
IMUNON, Inc. has announced its R&D Day scheduled for September 23, 2026, in New York City, focusing on the clinical progress of its investigational IL-12 immunotherapy, IMNN-001. The event will feature presentations from experts and a participant from the OVATION 1 trial, highlighting advancements in treating advanced ovarian cancer. The company aims to redefine treatment paradigms for women facing this disease.
Read more →IMNNIMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001
IMUNON, Inc. will host an R&D Day on September 23, 2026, in New York City, focusing on the Phase 3 OVATION 3 trial of its lead immunotherapy, IMNN-001. The event will feature presentations from oncology experts and a patient sharing her treatment journey. Attendees can expect updates on clinical progress and future milestones.
Read more →IMNNIMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update
IMUNON has reported its financial results for the second quarter of 2026, highlighting the promising candidate IMNN-001 for treating newly diagnosed ovarian cancer. The drug is the first frontline treatment to show potential for a clinically meaningful overall survival benefit. Enrollment for the Phase 3 OVATION 3 Study is anticipated to complete by the first half of 2029.
Read more →IMNN▲ +5.7%on this news
IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026
IMUNON, Inc. will host a conference call on August 11, 2026, to discuss its second quarter financial results and provide updates on its clinical development program, particularly the Phase 3 trial of IMNN-001 for advanced ovarian cancer. The call will include details on the company's progress and future plans.
Read more →IMNNIMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
IMUNON, Inc. has reported strong enrollment momentum in its Phase 3 OVATION 3 trial for IMNN-001 in advanced ovarian cancer. The trial has exceeded enrollment expectations, with a rate of 0.5 patients per site per month, surpassing the planned rate. The positive momentum is attributed to promising survival data and a well-tolerated safety profile observed in previous studies.
Read more →IMNNIMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development
IMUNON, Inc. announced that data on its IL-12 immunotherapy, IMNN-001, will be presented at the inaugural AACR Conference on Drug Discovery and Development. The data supports the potential of IMNN-001 to improve outcomes in advanced ovarian cancer through localized delivery of IL-12. The presentation underscores the company's innovative TheraPlas® platform and its ongoing Phase 3 trial, OVATION-3.
Read more →IMNN▼ -5.6%on this newsshared move
IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
IMUNON, Inc. announced positive preliminary data from its Phase 2 MRD clinical trial of IMNN-001 for advanced ovarian cancer. The study showed a lower rate of minimal residual disease and higher clearance of circulating tumor DNA compared to control. The favorable safety profile of IMNN-001 was consistent with previous studies, supporting its potential in frontline treatment. The findings bolster confidence as IMNN-001 advances into the pivotal Phase 3 OVATION 3 trial.
Read more →IMNNIMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
IMUNON, Inc. announced that its Phase 3 OVATION 3 study will continue without modifications, as recommended by the independent Data Monitoring Committee. The trial evaluates IMNN-001 in combination with standard chemotherapy for advanced ovarian cancer. Positive Phase 2 results indicated significant overall survival improvements, and the trial is on track to enroll 80 participants by Q1 2027.
Read more →IMNNIMUNON to Present at the Life Sciences Investor Forum on June 25th
IMUNON, Inc. will present at the Life Sciences Investor Forum on June 25, 2026. Dr. Stacy Lindborg, CEO, will discuss the company's Phase 3 DNA-mediated immunotherapy and its ongoing clinical programs. Investors can participate in real-time Q&A during the event, with an archived version available later. IMUNON focuses on innovative treatments for various diseases.
Read more →IMNNIMUNON Announces Up to $10 Million Cash Financing
IMUNON, Inc. announced a $10 million cash financing aimed at supporting its Phase 3 OVATION 3 clinical trial for IMNN-001 in advanced ovarian cancer. The financing includes issuance of preferred stock and secured promissory notes, with proceeds expected to enhance the company’s capital position. Updated clinical data from an earlier Phase 2 study has indicated improved survival outcomes for patients treated with IMNN-001 in combination with standard chemotherapy. This financing is seen as a strategic move to bolster shareholder value while progressing in clinical trials.
Read more →IMNNIMUNON Reports First Quarter 2026 Financial Results Provides Business Update
IMUNON, Inc. has reported its financial results for Q1 2026 alongside a business update on its lead candidate IMNN-001 for advanced ovarian cancer. The drug has shown promising overall survival benefits in the Phase 2 OVATION 2 study, with recent data indicating a median increase of 14.7 months compared to standard chemotherapy. The ongoing Phase 3 OVATION 3 trial is expected to conclude by Q1 2029, and IMUNON is aligned for a potential BLA filing based on this data. However, the company also reported a net loss of $4.3 million for the quarter, amid rising operational costs.
Read more →IMNNIMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026
IMUNON, Inc. will hold a conference call on May 12, 2026, to discuss its Q1 financial results and provide updates on its clinical development program for IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer. The company is currently conducting a Phase 3 trial for this candidate, which aims to enhance cancer-fighting responses in patients.
Read more →IMNNIMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
IMUNON, Inc. has reported its 2025 financial results alongside a business update on the progress of its lead therapy, IMNN-001, in advanced ovarian cancer. The company highlighted significant advancements in the Phase 3 OVATION 3 study, noting that IMNN-001 is the first frontline immunotherapy showing potential for a clinically meaningful survival benefit. Results from the Phase 2 OVATION 2 study indicate an improvement in median overall survival of over 14 months for patients treated with IMNN-001. The therapy’s promising safety profile and strong data support its role in transforming treatment options for women with advanced ovarian cancer.
Read more →IMNN▼ -5.4%on this news
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
IMUNON has reported updated Phase 2 data from the OVATION 2 trial, showing a median overall survival increase from 11.1 months to 14.7 months for women treated with IMNN-001. Additionally, patients receiving IMNN-001 alongside standard chemotherapy and PARP inhibitors experienced a median overall survival of 24.2 months. Enrollment for the Phase 3 trial is progressing ahead of schedule, reflecting strong interest in the treatment.
Read more →About Imunon, Inc.
Headquarters997 LENOX DRIVE, LAWRENCEVILLE, NJ, 08648
BIOPHARMAWATCH ELITE PLUS
Trade the next IMNN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime